SCHEMBL13036074

SCHEMBL13036074

Cc1cc(-c2ccncc2)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.50
CYP11B1 P15538 3/20 0.50
CYP11B2 P19099 3/20 0.50
GRIN2B Q13224 3/20 0.48
MAPK14 Q16539 1/20 0.47
DAPK3 O43293 1/20 0.46
NTRK1 P04629 1/20 0.46
PIM1 P11309 1/20 0.46
FLT3 P36888 1/20 0.46
GSK3B P49841 1/20 0.46
ROCK1 Q13464 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
QDPR P09417 1/20 0.45
GRIN1 Q05586 2/20 0.45
CSF1R P07333 1/20 0.44
KIF11 P52732 2/20 0.43
BLM P54132 1/20 0.43
CYP3A4 P08684 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13036104 0.83 CYP17A1 (0.50) CYP17A1CYP11B1CYP11B2MAPK14MAPT
SCHEMBL1911837 0.80 NPC1 (0.58) MAPK14NTRK1MAPTLMNAQDPR
SCHEMBL5762155 0.78 ACHE (0.48) DAPK3NTRK1PIM1FLT3GSK3B
SCHEMBL30947605 0.78 GRIN2B (0.47) GRIN2BDAPK3NTRK1PIM1FLT3
SCHEMBL16906614 0.78 KIF11 (0.51) DAPK3NTRK1PIM1FLT3GSK3B
SCHEMBL2665947 0.77 MKNK1 (0.56) CYP17A1CYP11B1CYP11B2GRIN2BDAPK3
SCHEMBL11689482 0.77 ESR2 (0.50) DAPK3NTRK1PIM1FLT3GSK3B
SCHEMBL29434804 0.77 ESR2 (0.50) DAPK3NTRK1PIM1FLT3GSK3B
SCHEMBL2090822 0.77 DAPK3 (0.44) GRIN2BDAPK3NTRK1PIM1FLT3
SCHEMBL5327942 0.75 DAPK3 (0.42) GRIN2BDAPK3NTRK1PIM1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 US disclosed
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 US disclosed
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
WO-2010130034-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 WO disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 US disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 CYP17A1 2523/4885CYP11B1 2617/4885CYP11B2 3410/4885
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 CYP17A1 2523/4885CYP11B1 2617/4885CYP11B2 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.